Publications by authors named "Y Igawa"
Introduction: Advances in the early detection and treatment of cancer have significantly improved the prognosis of patients with cancer. Tyrosine kinase inhibitors (TKIs) are effective targeted treatments for various malignancies that act by inhibiting kinase activity. Although these drugs share a common mechanism of action, they differ in their targeted kinases, pharmacokinetics, and side effects.
View Article and Find Full Text PDFBackground/aim: Thymic carcinoma is a rare cancer with poor prognosis in unresectable cases. Treatment efficacy of carboplatin+paclitaxel (CP), lenvatinib, S-1, and sunitinib remains uncertain, with some patients experiencing increased post-treatment liver metastasis.
Patients And Methods: We performed a retrospective analysis of patients with metastatic thymic carcinoma who received chemotherapy between 2006 and 2023 at the National Cancer Center Hospital.
Article Synopsis
- The study aimed to analyze clinical features of patients with interstitial cystitis (IC) and bladder pain syndrome (BPS) by using a patient registry in Japan, classifying patients based on cystoscopic findings.
- A total of 529 patients from 14 university hospitals were included, showing that 66.5% had IC, with these patients being older and predominantly female, and with more comorbid autoimmune diseases.
- Results indicated that patients with IC experienced worse symptoms, quality of life, and bladder function compared to those with BPS, with specific bladder measurements significantly correlating with pain levels in IC patients.
Objectives: Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, causes distinct adverse events (AEs), including hyperlipidemia and central nervous system (CNS) disorders. Although dose modifications are recommended to manage these AEs, whether dose modifications can achieve optimal blood lorlatinib concentrations and reduce the incidence of lorlatinib-induced AEs remains unclear. Therefore, we investigated the association between lorlatinib exposure and AEs in each patient.
View Article and Find Full Text PDFArticle Synopsis
- Shiga toxin-producing E. coli (STEC) causes severe gastrointestinal issues, particularly linked to Stx2, which poses greater risks than Stx1.
- A study of 71 strains in the O145:H28 lineage reveals the dynamic nature of Stx phages, including their acquisition, transfer, and variations affecting Stx2 production levels.
- Short-tailed Stx2 phages are associated with higher production levels of Stx2 than long-tailed variants, highlighting genetic differences that influence these levels.